DDInter1812 DDInter899
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Tinzaparin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Tinzaparin {u} may lead to a major life threatening interaction when taken with {v} Abciximab
Tinzaparin {u} may lead to a major life threatening interaction when taken with {v} Acalabrutinib
Tinzaparin may cause a minor interaction that can limit clinical effects when taken with Chamomile
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Tinzaparin may lead to a major life threatening interaction when taken with Abciximab
Tinzaparin may lead to a major life threatening interaction when taken with Acalabrutinib